Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Finished Goods (2020 - 2025)

IGC Pharma (IGC) has disclosed Finished Goods for 6 consecutive years, with $212000.0 as the latest value for Q3 2025.

  • Quarterly Finished Goods fell 47.52% to $212000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $212000.0 through Sep 2025, down 47.52% year-over-year, with the annual reading at $256000.0 for FY2025, 41.95% down from the prior year.
  • Finished Goods for Q3 2025 was $212000.0 at IGC Pharma, down from $271000.0 in the prior quarter.
  • The five-year high for Finished Goods was $1.0 million in Q3 2021, with the low at $212000.0 in Q3 2025.
  • Average Finished Goods over 5 years is $591631.6, with a median of $533000.0 recorded in 2023.
  • The sharpest move saw Finished Goods skyrocketed 222.95% in 2021, then crashed 47.52% in 2025.
  • Over 5 years, Finished Goods stood at $889000.0 in 2021, then fell by 20.58% to $706000.0 in 2022, then fell by 27.62% to $511000.0 in 2023, then decreased by 28.77% to $364000.0 in 2024, then crashed by 41.76% to $212000.0 in 2025.
  • According to Business Quant data, Finished Goods over the past three periods came in at $212000.0, $271000.0, and $256000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.